Testimony Before the FDA’s Drug Safety and Risk Management Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee Regarding a Hydrocodone-Acetaminophen-Promethazine Combination Product November 2, 2020
Testimony Before the FDA’s Vaccines and Related Biological Products Advisory Committee Regarding the Development, Authorization, and Licensure of Vaccines to Prevent COVID-19 October 22, 2020
Testimony Before the FDA’s Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Regarding the Combination Drug Olanzapine/Samidorphan Intended to Treat Schizophrenia and Bipolar Disorder October 9, 2020
Testimony Before the FDA’s Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Regarding an Oral Amphetamine Product Intended to be Abuse-Deterrent October 8, 2020
Comments on the FDA’s Proposal to Exclude 19 Bulk Drug Substances From the 503B Bulks List for Pharmacy Compounding by Outsourced Facilities September 29, 2020
Letter to the Secretary of Health and Human Services and Senior FDA and NIH Officials Opposing Emergency Use Authorization for Any COVID-19 Vaccine August 6, 2020